We next examined if pharmacologic inhibition of RhoA could reduce the type I IFN signaling pathway in PBMCs obtained from lupus patients with high type I IFN scores (see Supplementary, Table 2 for patient characteristics). The gene discussed is RHOA; the disease is systemic lupus erythematosus.